JP2022539157A5 - - Google Patents

Info

Publication number
JP2022539157A5
JP2022539157A5 JP2021577431A JP2021577431A JP2022539157A5 JP 2022539157 A5 JP2022539157 A5 JP 2022539157A5 JP 2021577431 A JP2021577431 A JP 2021577431A JP 2021577431 A JP2021577431 A JP 2021577431A JP 2022539157 A5 JP2022539157 A5 JP 2022539157A5
Authority
JP
Japan
Prior art keywords
polypeptide
sequence
cancer
cells
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021577431A
Other languages
English (en)
Japanese (ja)
Other versions
JP7887250B2 (ja
JP2022539157A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2020/051557 external-priority patent/WO2020260897A1/en
Publication of JP2022539157A publication Critical patent/JP2022539157A/ja
Publication of JP2022539157A5 publication Critical patent/JP2022539157A5/ja
Application granted granted Critical
Publication of JP7887250B2 publication Critical patent/JP7887250B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021577431A 2019-06-28 2020-06-26 新規な癌抗原及び方法 Active JP7887250B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19183318.5 2019-06-28
EP19183318 2019-06-28
EP20170163 2020-04-17
EP20170163.8 2020-04-17
PCT/GB2020/051557 WO2020260897A1 (en) 2019-06-28 2020-06-26 Novel cancer antigens and methods

Publications (3)

Publication Number Publication Date
JP2022539157A JP2022539157A (ja) 2022-09-07
JP2022539157A5 true JP2022539157A5 (cg-RX-API-DMAC7.html) 2023-07-05
JP7887250B2 JP7887250B2 (ja) 2026-07-09

Family

ID=71266763

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021577431A Active JP7887250B2 (ja) 2019-06-28 2020-06-26 新規な癌抗原及び方法

Country Status (11)

Country Link
US (1) US20220220175A1 (cg-RX-API-DMAC7.html)
EP (1) EP3990006A1 (cg-RX-API-DMAC7.html)
JP (1) JP7887250B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220029561A (cg-RX-API-DMAC7.html)
CN (1) CN114341169B (cg-RX-API-DMAC7.html)
AU (1) AU2020302285A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021026364A2 (cg-RX-API-DMAC7.html)
CA (1) CA3141553A1 (cg-RX-API-DMAC7.html)
IL (1) IL289200A (cg-RX-API-DMAC7.html)
MX (1) MX2021015765A (cg-RX-API-DMAC7.html)
WO (1) WO2020260897A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119978090A (zh) 2018-10-19 2025-05-13 弗朗西斯·克里克研究所有限公司 新的癌抗原和方法
EP3994156A1 (en) 2019-07-05 2022-05-11 The Francis Crick Institute Limited Novel cancer antigens and methods
EP4136096A1 (en) * 2020-04-17 2023-02-22 The Francis Crick Institute Limited Antigen pool
EP4136097A1 (en) * 2020-04-17 2023-02-22 The Francis Crick Institute Limited Fusion proteins of ctl antigens for treating melanoma
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0871747A1 (en) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunostimulation mediated by gene-modified dendritic cells
US6770456B1 (en) 1998-07-29 2004-08-03 Ludwig Institute For Cancer Research Endogenous retrovirus tumor associated nucleic acids and antigens
JP2003304877A (ja) * 2002-04-15 2003-10-28 Keio Gijuku ヒト色素細胞特異分子
EP1586330A1 (en) 2004-04-16 2005-10-19 Georg-August-Universität Göttingen Vaccination against malignant melanoma
EP2402447A1 (en) 2005-03-30 2012-01-04 Viroxis Endogenous retrovirus and proteins encoded by env gene as a target for cancer treatment
AT502292B1 (de) 2005-05-11 2010-04-15 Avir Green Hills Biotechnology Melanomdiagnose
WO2007109583A2 (en) 2006-03-17 2007-09-27 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject
US20080019979A1 (en) 2006-05-22 2008-01-24 Feng Wang-Johanning HERV-K Antigens, Antibodies, and Methods
WO2009039244A2 (en) 2007-09-18 2009-03-26 Genizon Biosciences Inc. Genemap of the human genes associated with crohn's disease
MA43477A1 (fr) * 2016-04-21 2019-05-31 Immatics Biotechnologies Gmbh Immunothérapie contre le mélanome et d'autres cancers
CN113329761A (zh) * 2018-09-04 2021-08-31 特雷斯生物有限公司 肽疫苗
CN119978090A (zh) 2018-10-19 2025-05-13 弗朗西斯·克里克研究所有限公司 新的癌抗原和方法

Similar Documents

Publication Publication Date Title
EP1658097B1 (en) Nucleotide and cellular vaccine composition
US9463228B2 (en) Application of mRNA for use as a therapeutic against tumour diseases
RU2526510C2 (ru) Композиция для лечения рака легких, прежде всего, немелкоклеточного рака легких (нмкрл)
JP5709264B2 (ja) ワクチン組成物および方法
JPWO2008096831A1 (ja) 癌の治療剤
JP2007523863A (ja) 予防又は治療目的のためのmhcクラスi拘束性エピトープに対する免疫応答を誘発し、増強し、維持する方法
JP2022538609A5 (cg-RX-API-DMAC7.html)
JP2022514116A5 (cg-RX-API-DMAC7.html)
JP2022539585A5 (cg-RX-API-DMAC7.html)
JP2022540396A5 (cg-RX-API-DMAC7.html)
CA2466530A1 (en) Allogenic vaccine that contains a costimulatory polypeptide-expressing tumor cell
CN119770632A (zh) 诱导免疫应答的组合物和方法
CN101146550A (zh) 用于预防或治疗目的的激发、增强和维持对i类mhc-限制性表位的免疫应答的方法
KR101810840B1 (ko) 암의 예방 및 치료용 msi-특이적 프레임쉬프트 펩티드(fsp)
Zhang et al. Recombinant cell-penetrating trichosanthin synergizes anti-PD-1 therapy in colorectal tumor
US20260021184A1 (en) Cancer Antigens and Methods
WO2025224446A1 (en) Novel cancer antigens and methods
JP2023522193A5 (cg-RX-API-DMAC7.html)
WO2015005479A1 (ja) 腫瘍抗原ペプチド
Hersey et al. Melanoma vaccines
CN118843474A (zh) 用于肺癌的治疗性rna
CLONES Genes Coding for Antigens Recognized on Human Tumors by Autologous Cytolytic T Lymphocytes zyxwvutsrqpon
Class et al. Patent application title: APPLICATION OF mRNA FOR USE AS A THERAPEUTIC AGAINST TUMOUR DISEASES Inventors: Ingmar Hoerr (Tubingen, DE) Florian Von Der MÜlbe (Stuttgart, DE) Florian Von Der MÜlbe (Stuttgart, DE) Steve Pascolo (Tubingen, DE) Steve Pascolo (Tubingen, DE) Assignees: CureVac AG
Dummer Vaccine therapy in advanced melanoma-State of the art
HK1140961A (en) Therapeutic agent for cancer